Agile Initiates Phase 3 SECURE Study for Twirla™

September 16, 2014

New Insights on Breast Cancer Research (video)

August 27, 2014

Transcept Pharmaceuticals and Paratek Pharmaceuticals Sign Merger Agreement

July 1, 2014

Seragon Pharmaceuticals Announces Acquisition Agreement with Genentech

July 1, 2014

Cidara Therapeutics Completes $32 Million Series A Financing

June 30, 2014

FDA Approves Durata Therapeutics' DALVANCE™ for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults

May 23, 2014

Optegra Invests in LENSAR™ Femtosecond Cataract Laser Across all its UK Hospitals

February 17, 2014

FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia

January 12, 2014

BioCentury TV: Biotech's Record Run - Can it Continue? (video)

January 12, 2014

ViewRay Closes a $30M Financing to Expedite Commercialization of its MRI-Guided Radiation Therapy System

December 17, 2013

IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy

November 13, 2013

Lensar Secures $87 Million in Financing to Support Market Expansion of Its Laser Cataract Surgery System

October 02, 2013

SafeStitch Medical Completes Merger with TransEnterix

September 4, 2013

Aragon Pharmaceuticals, Inc. Announces Closing of Its Acquisition by Johnson & Johnson

August 19, 2013

SafeStitch Medical Announces Definitive Agreement to Merge with TransEnterix

August 14, 2013

Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

August 12, 2013

Dennis Purcell talks about the boost in pharmaceutical and biotech earnings on CNN

July 30, 2013

Esperion Therapeutics, Inc. Announces Pricing of Initial Public Offering

June 26, 2013

Aragon Pharmaceuticals Announces Acquisition by Johnson & Johnson

June 17, 2013

Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock

May 14, 2013

Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

February 25, 2013

Drug Tames Refractory AML

December 9, 2012

Advion Announces Full Integration with Agilent Technologies Liquid Chromatography Systems

December 8, 2012

Pfizer To Acquire NextWave Pharmaceuticals

October 22, 2012

NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR™ for Once-Daily Treatment of ADHD

October 1, 2012

Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as Monotherapy in Relapsed or Refractory Acute Myeloid Leukemia

June 4, 2012

Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor

May 17, 2012

Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice

February 7, 2012

Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock

February 3, 2012

Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at The American Society of Hematology 53rd Annual Meeting

December 1, 2011

Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer

November 18, 2011

Quintiles Completes Acquisition of Advion BioServices

November 7, 2011

ZELTIQ Aesthetics, Inc. Prices Initial Public Offering

October 18, 2011

T2 Biosystems Completes $23 Million Series D Financing

August 10, 2011

Pernix Announces Pricing of $28 Million Underwritten Registered Direct Offering of Common Stock

July 21, 2011

Interim Data from Phase 2 Trial of AC220 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with FLT3-ITD Activating Mutations

June 13, 2011

MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug

May 26, 2011

Advion BioServices Opens Midwest Drug Discovery and Metabolism Center of Excellence

May 23, 2011

ARMGO Pharma Inc., Announces the Appointment of Dr. Sapan Shah as CEO

May 2, 2011

Advion BioServices to Open New Laboratory in Indianapolis to Provide Metabolism, ADME Screening, and Other Early-Stage Bioanalytical Services to Life Sciences Customers, including Lilly

March 1, 2011

Allergan and MAP Pharmaceuticals Announce Collaboration on LEVADEX™ Investigational Therapy for Acute Migraine

January 31, 2011

NextWave Pharmaceuticals Announces Launch of NEXICLON™ XR – First Extended-Release, Once-Daily Clonidine Oral Suspension and Tablet

January 6, 2011

Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering

November 5, 2010

Say Goodbye to Unwanted Love Handles: CoolSculpting by Zeltiq™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction

September 8, 2010

LensAR Laser System™ Receives FDA Clearance for Use in Cataract Surgery

May 18, 2010

Aragon Pharmaceuticals Secures $22 Million in Series B Financing

April 22, 2010

LensAR Strengthens Team with Appointments of Medical Monitor and Two Board Members

April 8, 2010

TRIA Beauty Announces the Launch of the TRIA Skin Clarifying System

April 5, 2010

FDA Grants Permanent Hair Reduction Labeling for Tria Laser Hair Removal System

January 11, 2010

VIVUS Announces Additional Results of Phase 3 avanafil Study in Erectile Dysfunction Showing Efficacy in 15 Minutes

January 11, 2010

Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuron Subsidiary

December 21, 2009

Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications

December 18, 2009

LensAR Inc. to Present Data from Laser Cataract Surgery Clinical Trial at the Annual Meeting of the American Academy of Ophthalmology

October 13, 2009

TransEnterix Secures $55 Million in Financing

October 7, 2009

Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic

October 08, 2009

Allos Therapeutics' FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma

September 25, 2009

Sirion Therapeutics Announces FDA Approval of Zirgan™ (ganciclovir ophthalmic gel) 0.15% for Herpetic Keratitis

September 16, 2009

VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities

September 9, 2009

Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR™ (diclofenac potassium) Liquid Filled Capsules

June 17, 2009

MAP Pharmaceuticals Phase 3 Trial of LEVADEX™ Migraine Product Candidate Meets All Four Primary Endpoints

May 26, 2009

SkinMedica to Co-promote ACZONE® (dapsone) Gel 5% to Pediatricians in the U.S.

May 11, 2009

Tria Beauty Announces New and Improved Tria Laser Hair Removal System

February 24, 2009

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

February 23, 2009

AstraZeneca and MAP Pharmaceuticals Announce Worldwide Collaboration to Develop and Commercialize Unit Dose Budesonide

December 19, 2008

Qnexa Meets Primary Endpoint by Demonstrating Superior Weight Loss over Components and Placebo in the 28-Week Equate Study (OB-301)

December 11, 2008

TRIA Beauty wins as the Prestige Skin Care Breakthrough Product of the Year

December 11, 2008

Ambit Biosciences Presents Data on its Targeted Cancer Therapeutic AC220 for Acute Myeloid Leukemia

December 9, 2008

Two Pralatrexate Studies Presented at the 50th Annual Meeting of the American Society of Hematology

December 6, 2008

Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy

October 26, 2008

CeNeRx BioPharma Completes $15 Million Series B Financing

October 17, 2008

Sirion Therapeutics Announces Positive Pivotal Uveitis Data For Durezol™

October 14, 2008

Allure Magazine Names Tria Laser a Beauty Breakthrough Product of 2008

September 17, 2008

Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX(TM) Phase IIb Study for Peyronie's Disease

September 17, 2008

Stiefel Laboratories Completes Acquisition of Barrier Therapeutics

August 6, 2008

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

July 14, 2008

Dynova Laboratories Brings OTC Healhcare Marketing Expertise To Natural Products Market, Acquires “Sinus Buster” Company

July, 2008

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX™ Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

June 03, 2008

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

April 7, 2008

New Microfluidic Technology for Proteomic Research

April 1, 2008

Advion Acquires the Assets of its BioSystems Manufacturing Partner

March 12, 2008

Barrier Therapeutics Announces Top Management Succession Plan

January 25, 2008

CeNeRx BioPharma Announces Successful Completion of Phase 1 Clinical Program for Novel Antidepressant Agent Tyrima™

January 15, 2008

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial of Unit Dose Budesonide in Children with Asthma

January 7, 2008